Abstract
Biocompatible mesoporous silica nanoparticles, containing the fluorescence dye fluorescein isothiocyanate (FITC), provide a promising system to deliver hydrophobic anticancer drugs to cancer cells. In this study, we investigated the mechanism of uptake of fluorescent mesoporous silica nanoparticles (FMSN) by cancer cells. Incubation with FMSN at different temperatures showed that the uptake was higher at 37°C than at 4°C. Metabolic inhibitors impeded uptake of FMSN into cells. The inhibition of FMSN uptake by nocodazole treatment suggests that microtubule functions are required. We also report utilization of mesoporous silica nanoparticles to deliver a hydrophobic anticancer drug paclitaxel to PANC-1 cancer cells and to induce inhibition of proliferation. Mesoporous silica nanoparticles may provide a valuable vehicle to deliver hydrophobic anticancer drugs to human cancer cells.
Similar content being viewed by others
References
Reynolds AR, Moein MS, Hodivala-Dilke K. Trends Mol Med 2003;9:2–4.
Van Vlerken LE, Amiji MM. Expert Opin Drug Deliv 2006;3:205–16.
Ebbesen M, Jensen TG. J Biomed Biotechnol 2006;2006:51516.
Brannon-Peppas L, Blanchette JO. Adv Drug Deliv Rev 2004;56:1649–59.
Kresge CT, Leonowicz ME, Roth WJ, Vartuli JC, Beck JS. Nature 1992;359:710–2.
Han YJ, Stucky GD, Butler A. J Am Chem Soc 1999;121:9897–8.
Lu J, Liong M, Zink JI, Tamanoi F. Small 2007;3:1341–6.
Canonico PG, Bird JWC. J Cell Biol 1969;43:367–71.
Chen J, Cha Y, Yuksel K, Gracy R, August J. J Biol Chem 1988;263:8754–8.
Lichstein HC, Soule MH. J Bacteriol 1944;47:231–8.
Heuser JE, Anderson RG. J Cell Biol 1989;108:389–400.
Wessing A, Bertram G, Zierold K. J Comp Physiol 1993;163:452.
Pearse BM, Crowther RA. Annu Rev Biophys Biophys Chem 1987;16:49–68.
Harvey WR, Maddrell SHP, Telfer WH, Wieczorek H. Amer Zool 1998;38:426–41.
Samson F, Donoso JA, Heller-Bettinger I, Watson D, Himes RH. J Pharmacol Exp Ther 1979;208:411–7.
Roma MG, Milkiewicz P, Elias E, Coleman R. Hepatology 2000;32:1342–56.
Chung TH, Wu SH, Yao M, Lu CW, Lin YS, Hung Y, et al. Biomaterials 2007;28:2959–66.
Kim JS, Yoon TJ, Yu KN, Noh MS, Woo M, Kim BG, et al. J Vet Sci 2006;7:321–6.
Gemeinhart RA, Luo D, Saltzman WM. Biotechnol Prog 2005;21:532–7.
Xing X, He X, Peng J, Wang K, Tan W. J Nanosci Nanotechnol 2005;5:1688–93.
Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. J Am Chem Soc 1971;93:2325–7.
Slowing I, Trewyn BG, Lin VS. J Am Chem Soc 2006;128:14792–3.
Luo D, Saltzman WM. Nat Biotechnol 2000;18:893–5.
Jin Y, Kannan S, Wu M, Zhao JX. Chem Res Toxicol 2007;20:1126–33.
Acknowledgments
This work is supported by US NIH grants CA32737 (F.T.) and ES015498 (A.N.), NSF grant DMR0346601 (J.Z.) and a grant from Edna E. and Susan E. Riley foundation. Monty Liong and Michael Kovochich are supported by the UC Lead Campus for Nanotoxicology Training and Research, funded by UC TSR&TP.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lu, J., Liong, M., Sherman, S. et al. Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnol 3, 89–95 (2007). https://doi.org/10.1007/s12030-008-9003-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12030-008-9003-3